Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 74

1.

The challenges of control groups, placebos and blinding in clinical trials of dietary interventions.

Staudacher HM, Irving PM, Lomer MCE, Whelans K.

Proc Nutr Soc. 2017 Jun 20:1-10. doi: 10.1017/S0029665117000350. [Epub ahead of print]

PMID:
28629483
2.

Diet Low in FODMAPs Reduces Symptoms in Patients with Irritable Bowel Syndrome and Probiotic Restores Bifidobacterium Species: a Randomized Controlled Trial.

Staudacher HM, Lomer MCE, Farquharson FM, Louis P, Fava F, Franciosi E, Scholz M, Tuohy KM, Lindsay JO, Irving PM, Whelan K.

Gastroenterology. 2017 Jun 15. pii: S0016-5085(17)35744-X. doi: 10.1053/j.gastro.2017.06.010. [Epub ahead of print]

PMID:
28625832
3.

Thioguanine in inflammatory bowel disease: Long-term efficacy and safety.

Ward MG, Patel KV, Kariyawasam VC, Goel R, Warner B, Elliott TR, Blaker PA, Irving PM, Marinaki AM, Sanderson JD.

United European Gastroenterol J. 2017 Jun;5(4):563-570. doi: 10.1177/2050640616663438. Epub 2016 Aug 1.

4.

Fermentable carbohydrates (FODMAPs) exacerbate functional gastrointestinal symptoms in patients with inflammatory bowel disease: a randomised, double-blind, placebo-controlled, cross-over, re-challenge trial.

Cox SR, Prince AC, Myers CE, Irving PM, Lindsay JO, Lomer MC, Whelan K.

J Crohns Colitis. 2017 May 19. doi: 10.1093/ecco-jcc/jjx073. [Epub ahead of print]

PMID:
28525543
5.

Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors.

Ward MG, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM.

Aliment Pharmacol Ther. 2017 Jul;46(2):150-161. doi: 10.1111/apt.14124. Epub 2017 May 8.

PMID:
28481014
6.

Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.

Dart RJ, Samaan MA, Powell N, Irving PM.

Clin Exp Gastroenterol. 2017 Mar 3;10:57-66. doi: 10.2147/CEG.S110547. eCollection 2017. Review.

7.

ECCO IBD Curriculum.

Lindsay JO, Irving PM, Mantzaris GJ, Panés J; ECCO Education Committee and ECCO Governing Board.

J Crohns Colitis. 2017 Jan 27. doi: 10.1093/ecco-jcc/jjx004. [Epub ahead of print] No abstract available.

PMID:
28172611
8.

Patient optimization for surgery relating to Crohn's disease.

Patel KV, Darakhshan AA, Griffin N, Williams AB, Sanderson JD, Irving PM.

Nat Rev Gastroenterol Hepatol. 2016 Dec;13(12):707-719. doi: 10.1038/nrgastro.2016.158. Epub 2016 Oct 26. Review.

PMID:
27780971
9.

Epithelia Use Butyrophilin-like Molecules to Shape Organ-Specific γδ T Cell Compartments.

Di Marco Barros R, Roberts NA, Dart RJ, Vantourout P, Jandke A, Nussbaumer O, Deban L, Cipolat S, Hart R, Iannitto ML, Laing A, Spencer-Dene B, East P, Gibbons D, Irving PM, Pereira P, Steinhoff U, Hayday A.

Cell. 2016 Sep 22;167(1):203-218.e17. doi: 10.1016/j.cell.2016.08.030. Epub 2016 Sep 15.

10.

Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.

Melmed GY, Irving PM, Jones J, Kaplan GG, Kozuch PL, Velayos FS, Baidoo L, Sparrow MP, Bressler B, Cheifetz AS, Devlin SM, Raffals LE, Vande Casteele N, Mould DR, Colombel JF, Dubinsky M, Sandborn WJ, Siegel CA.

Clin Gastroenterol Hepatol. 2016 Sep;14(9):1302-9. doi: 10.1016/j.cgh.2016.05.010. Epub 2016 May 14.

PMID:
27189916
11.

The impact of updated NICE guidelines on biologic treatment of ulcerative colitis: reflections on past practices, the changing present and implications for the future.

Samaan MA, Irving PM.

Expert Opin Biol Ther. 2016 Aug;16(8):975-7. doi: 10.1080/14712598.2016.1189529. Epub 2016 May 31. No abstract available.

PMID:
27186809
12.

Recommendations for Quality Colonoscopy Reporting for Patients with Inflammatory Bowel Disease: Results from a RAND Appropriateness Panel.

Devlin SM, Melmed GY, Irving PM, Rubin DT, Kornbluth A, Kozuch PL, Raffals LE, Velayos FS, Sparrow MP, Baidoo L, Bressler B, Cheifetz AS, Jones J, Kaplan GG, Siegel CA.

Inflamm Bowel Dis. 2016 Jun;22(6):1418-24. doi: 10.1097/MIB.0000000000000764.

PMID:
27057680
13.

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?

Ward MG, Irving PM, Sparrow MP.

World J Gastroenterol. 2015 Oct 28;21(40):11331-42. doi: 10.3748/wjg.v21.i40.11331. Review.

14.

Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.

Tew GW, Hackney JA, Gibbons D, Lamb CA, Luca D, Egen JG, Diehl L, Eastham Anderson J, Vermeire S, Mansfield JC, Feagan BG, Panes J, Baumgart DC, Schreiber S, Dotan I, Sandborn WJ, Kirby JA, Irving PM, De Hertogh G, Van Assche GA, Rutgeerts P, O'Byrne S, Hayday A, Keir ME.

Gastroenterology. 2016 Feb;150(2):477-87.e9. doi: 10.1053/j.gastro.2015.10.041. Epub 2015 Oct 30.

15.

Prevalence and Risk Factors for Functional Vitamin B12 Deficiency in Patients with Crohn's Disease.

Ward MG, Kariyawasam VC, Mogan SB, Patel KV, Pantelidou M, Sobczyńska-Malefora A, Porté F, Griffin N, Anderson SH, Sanderson JD, Harrington DJ, Irving PM.

Inflamm Bowel Dis. 2015 Dec;21(12):2839-47. doi: 10.1097/MIB.0000000000000559.

PMID:
26296064
16.

Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal Inflammation.

Powell N, Lo JW, Biancheri P, Vossenkämper A, Pantazi E, Walker AW, Stolarczyk E, Ammoscato F, Goldberg R, Scott P, Canavan JB, Perucha E, Garrido-Mesa N, Irving PM, Sanderson JD, Hayee B, Howard JK, Parkhill J, MacDonald TT, Lord GM.

Gastroenterology. 2015 Aug;149(2):456-67.e15. doi: 10.1053/j.gastro.2015.04.017. Epub 2015 Apr 25.

17.

Toxicity and response to thiopurines in patients with inflammatory bowel disease.

Goldberg R, Irving PM.

Expert Rev Gastroenterol Hepatol. 2015 Jul;9(7):891-900. doi: 10.1586/17474124.2015.1039987. Epub 2015 Apr 27. Review.

PMID:
25915575
18.

Clinical effectiveness and economic costs of group versus one-to-one education for short-chain fermentable carbohydrate restriction (low FODMAP diet) in the management of irritable bowel syndrome.

Whigham L, Joyce T, Harper G, Irving PM, Staudacher HM, Whelan K, Lomer MC.

J Hum Nutr Diet. 2015 Dec;28(6):687-96. doi: 10.1111/jhn.12318. Epub 2015 Apr 14.

PMID:
25871564
19.

Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.

Canavan JB, Scottà C, Vossenkämper A, Goldberg R, Elder MJ, Shoval I, Marks E, Stolarczyk E, Lo JW, Powell N, Fazekasova H, Irving PM, Sanderson JD, Howard JK, Yagel S, Afzali B, MacDonald TT, Hernandez-Fuentes MP, Shpigel NY, Lombardi G, Lord GM.

Gut. 2016 Apr;65(4):584-94. doi: 10.1136/gutjnl-2014-306919. Epub 2015 Feb 24.

20.

Distinct management issues with Crohn's disease of the small intestine.

Fong SC, Irving PM.

Curr Opin Gastroenterol. 2015 Mar;31(2):92-7. doi: 10.1097/MOG.0000000000000149. Review.

PMID:
25594888

Supplemental Content

Loading ...
Support Center